Shingles Vaccine Market Size

Shingles Vaccine Market Size

The global shingles vaccine market size was valued at USD 4.9 billion in 2024 and is expected to exhibit growth at a CAGR of 10.1% from 2025 to 2034. High market growth can be attributed to the rising geriatric population, favorable reimbursement policies, and growing awareness about shingles and their complications, among other contributing factors.

Shingles, or herpes zoster, is caused by the reactivation of the varicella-zoster virus and primarily affects individuals over the age of 50. The risk of shingles and its severe complications, including postherpetic neuralgia, increases significantly with age, making vaccination an important preventive measure for older adults. As the global population ages, demand for shingles vaccines is expected to rise to meet the needs of this vulnerable demographic.
 

Additionally, public health campaigns and educational initiatives have raised awareness of the health risks associated with shingles, particularly for older adults. Health organizations are actively working to inform people about the importance of vaccination in preventing shingles and reducing the likelihood of long-term pain. As a result, more people within the geriatric population, along with their caregivers, are opting for vaccination as a proactive health measure, fueling growth in the shingles vaccine market.
 

The shingles vaccine is an immunization specifically designed to prevent shingles, a painful skin rash caused by the reactivation of the varicella-zoster virus, which also causes chickenpox. The vaccine works by boosting the body’s immune response to the virus, thereby reducing the likelihood of reactivation in older adults, who are more susceptible to shingles.